Real-world practices in RAS wild-type metastatic colorectal cancer patients treated with targeted agents in the first-line a nationwide onco-colon Turkey registry

Authors : Dilek Tatlıdede, Çağatay Arslan, Mahmut Emre Yıldırım, Abdurrahman Işıkdoğan, Nuri Karadurmuş, Bülent Karabulut, Erdem Çubukçu, İrfan Çiçin, Şuayib Yalçın, Hacı Mehmet Türk, Cemil Bilir, Mustafa Karaca, Mehmet Artaç, Mehmet Ali Şendur, Ahmet Alacacıoğlu, Eda Tanrıkulu, Faysal Dane, Ahmet Bilici, Yağmur Çakmak, Oktay Bozkurt, Hakan Harputluoglu, Sinemis Çelik, Deniz Tural, Abdullah Sakin, Çağlayan Geredeli, Başak Öven, Melike Özçelik, Umut Kefeli, Mahmut Gümüş

Pages : 42-51

Doi:10.21673/anadoluklin.1675424

View : 108 | Download : 400

Publication Date : 2026-01-24

Article Type : Research Paper

Abstract :Aim: Efficacy of antiepidermal growth factor receptor (anti-EGFR) agents has been demonstrated in metastatic colorectal cancer (mCRC). Real-world evidence is especially important to detect patient findings outside of clinical trials. Therefore; we aimed to investigate the real-world data in patients with RAS wild-type mCRC. Methods: Medical records from 28 centers were collected for patients diagnosed with mCRC between January 2016 and April 2019. Patients were compared according to the first-line biological treatments as anti-EGFR group (Group A (panitumumab) and B (cetuximab)) and anti-VEGF group (Group C). Results: A total of 1064 patients with documented RAS wild-type mCRC were evaluated. Of these; 33%; 37% and 30% were treated with regimens including panitumumab; cetuximab; and anti-VEGF in the first-line; respectively. Overall response rate was 46.4%; 41.9% and 41.5% in A; B; and C groups; respectively (p = 0;170). The median OS was 26; 27; and 23 months in A; B and C group respectively (p = 0.044). The median PFS of the patients that treated with panitumumab; cetuximab and bevacizumab was 11;6; 11;0 and 9;6 months respectively (p = 0.012). ECOG performance status (PS) 0-1 and Braf wild-type status were found as independent prognostic factors in multivariate analysis for OS and only BRAF wild-type status for PFS (p<0.05). Conclusion: This analysis of real-world data confirms the comparable efficacy of anti-EGFR agents in RAS wild-type mCRC. However; anti-EGFR treatment provides PFS and OS advantage when compared with anti-VEGF treatment in these patients. Also; Braf wild-type tumors had improved PFS and OS in RAS wild-type mCRC.
Keywords : Epidermal büyüme faktörü reseptörü, kolorektal neoplaziler, setuksimab, panitumumab, vasküler endotelyal büyüme faktörü B

ORIGINAL ARTICLE URL